Active Biotech and Teva together in a Phase II clinical trial against Huntington’s disease

Active Biotech announced today that its partner Teva Pharmaceutical will initiate a phase II clinical trial to evaluate the efficacy and safety of oral laquinimod for the treatment of Huntington’s disease.

Laquinimod is a once-daily oral, investigational, CNS-active immunomodulator with a novel mechanism of action being developed primarily for the treatment of relapsing-remitting multiple sclerosis (RRMS) and progressive forms of multiple sclerosis. In extensive non-clinical and clinical studies, laquinimod has demonstrated both anti-inflammatory and neuroprotective properties and effects that have been shown to provide clinically meaningful results.

Active Biotech is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Tasquinimod another Active Biotech’s drug, for the treatment of prostate cancer, is in pivotal phase. In addition, laquinimod has concluded Phase II development for Crohn’s and Lupus. The company has two additional projects in clinical development: Anyara, primarily for the treatment of renal cell cancer and the orally administered compound paquinimod for systemic sclerosis.

Previous post

Relive BIO 2014, the World's Biggest Biotech Convention

Next post

ProQR Therapeutics files for a $75m IPO to compete with Vertex Pharmaceuticals

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.